<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473924</url>
  </required_header>
  <id_info>
    <org_study_id>20-31500</org_study_id>
    <nct_id>NCT04473924</nct_id>
  </id_info>
  <brief_title>Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk</brief_title>
  <acronym>STIFLE-RISK</acronym>
  <official_title>Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections are common and associated with poor outcomes as well as high financial costs after&#xD;
      kidney transplantation. Identifying and implementing strategies to reduce infections after&#xD;
      kidney transplantation is important for improving patient outcomes. This study seeks to&#xD;
      determine the feasibility of body surface area-based dosing of mycophenolate compared to&#xD;
      standard dosing of mycophenolate in a pilot randomized controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enrollment rate in a trial of BSA-based vs. fixed dosing of mycophenolate</measure>
    <time_frame>6 months</time_frame>
    <description>Assess the ratio of participants screened to enrolled into the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of a trial of BSA-based vs. fixed dosing of mycophenolate</measure>
    <time_frame>6 months</time_frame>
    <description>Assess the rate of dropout from the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collect pilot data of efficacy in a trial of BSA-based vs. fixed dosing of mycophenolate</measure>
    <time_frame>6 months</time_frame>
    <description>Collect pilot data on number of overall hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collect pilot data of efficacy in a trial of BSA-based vs. fixed dosing of mycophenolate</measure>
    <time_frame>6 months</time_frame>
    <description>Collect pilot data on infectious-related hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collect pilot data of efficacy in a trial of BSA-based vs. fixed dosing of mycophenolate</measure>
    <time_frame>6 months</time_frame>
    <description>Collect pilot data on incidence of leukopenia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Infection</condition>
  <condition>Transplant;Failure,Kidney</condition>
  <arm_group>
    <arm_group_label>Body surface area-based mycophenolate dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group will receive mycophenolate mofetil 750 mg/m^2/day divided into twice daily dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard (fixed) dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator group will receive standard fixed dosing of mycophenolate mofetil 1000 mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Body surface area-based dosing of mycophenolate</description>
    <arm_group_label>Body surface area-based mycophenolate dosing</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Standard (fixed) dosing of mycophenolate</description>
    <arm_group_label>Standard (fixed) dosing</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult transplant recipients â‰¥18 years of age who have a functional allograft and have&#xD;
             undergone kidney transplantation between six months and two years prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  Receiving mycophenolate mofetil for maintenance transplant immunosuppression at the&#xD;
             time of the screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of rejection on routine six month post-transplant biopsy&#xD;
&#xD;
          -  Prior intolerance to mycophenolate mofetil necessitating drug discontinuation&#xD;
&#xD;
          -  Are or are planning to become pregnant, due to inability to take mycophenolate&#xD;
&#xD;
          -  Are marginally housed, due to concerns regarding routine follow-up&#xD;
&#xD;
          -  Are actively participating in a different interventional trial that may affect&#xD;
             immunosuppression dosing&#xD;
&#xD;
          -  Are unwilling to consent to participate&#xD;
&#xD;
          -  Institutionalized individuals or prisoners&#xD;
&#xD;
          -  Are actively abusing illicit drugs or alcohol&#xD;
&#xD;
          -  Have a history of poor or doubtful compliance (e.g., frequently missed appointments)&#xD;
&#xD;
          -  Have cognitive impairment prohibiting participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine Ku, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elaine Ku, MD</last_name>
    <phone>415-353-2507</phone>
    <email>Elaine.Ku@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alex Dinh, MD</last_name>
    <email>Alex.Dinh@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alex Dinh, MD</last_name>
      <email>alex.dinh@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

